A BILL 
To prohibit brand name drug manufacturers from compen-
sating generic drug manufacturers to delay the entry 
of a generic drug into the market, and to prohibit bio-
logical product manufacturers from compensating bio-
similar and interchangeable product manufacturers to 
delay entry of biosimilar and interchangeable products, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
01:30 Mar 19, 2019
H1499
2 
•HR 1499 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Protecting Consumer 
2
Access to Generic Drugs Act of 2019’’. 
3
SEC. 2. UNLAWFUL AGREEMENTS. 
4
(a) AGREEMENTS PROHIBITED.—Subject to sub-
5
sections (b) and (c), it shall be unlawful for an NDA or 
6
BLA holder and a subsequent filer to enter into, or carry 
7
out, an agreement resolving or settling a covered patent 
8
infringement claim on a final or interim basis if under 
9
such agreement— 
10
(1) a subsequent filer directly or indirectly re-
11
ceives from such holder anything of value, including 
12
an exclusive license; and 
13
(2) the subsequent filer agrees to limit or fore-
14
go research on, or development, manufacturing, 
15
marketing, or sales, for any period of time, of the 
16
covered product that is the subject of the application 
17
described in subparagraph (A) or (B) of subsection 
18
(f)(8). 
19
(b) EXCLUSION.—It shall not be unlawful under sub-
20
section (a) if a party to an agreement described in such 
21
subsection demonstrates by clear and convincing evidence 
22
that the value described in subsection (a)(1) is compensa-
23
tion solely for other goods or services that the subsequent 
24
filer has promised to provide. 
25
01:30 Mar 19, 2019
H1499
3 
•HR 1499 IH
(c) LIMITATION.—Nothing in this section shall pro-
1
hibit an agreement resolving or settling a covered patent 
2
infringement claim in which the consideration granted by 
3
the NDA or BLA holder to the subsequent filer as part 
4
of the resolution or settlement includes only one or more 
5
of the following: 
6
(1) The right to market the covered product 
7
that is the subject of the application described in 
8
subparagraph (A) or (B) of subsection (f)(8) in the 
9
United States before the expiration of— 
10
(A) any patent that is the basis of the cov-
11
ered patent infringement claim; or 
12
(B) any patent right or other statutory ex-
13
clusivity that would prevent the marketing of 
14
such covered product. 
15
(2) A payment for reasonable litigation ex-
16
penses not to exceed $7,500,000 in the aggregate. 
17
(3) A covenant not to sue on any claim that 
18
such covered product infringes a patent. 
19
(d) ENFORCEMENT BY FEDERAL TRADE COMMIS-
20
SION.— 
21
(1) GENERAL APPLICATION.—The requirements 
22
of this section apply, according to their terms, to an 
23
NDA or BLA holder or subsequent filer that is— 
24
01:30 Mar 19, 2019
H1499
4 
•HR 1499 IH
(A) a person, partnership, or corporation 
1
over which the Commission has authority pur-
2
suant to section 5(a)(2) of the Federal Trade 
3
Commission Act (15 U.S.C. 45(a)(2)); or 
4
(B) a person, partnership, or corporation 
5
over which the Commission would have author-
6
ity pursuant to such section but for the fact 
7
that such person, partnership, or corporation is 
8
not organized to carry on business for its own 
9
profit or that of its members. 
10
(2) UNFAIR OR DECEPTIVE ACTS OR PRACTICES 
11
ENFORCEMENT AUTHORITY.— 
12
(A) IN GENERAL.—A violation of this sec-
13
tion shall be treated as an unfair or deceptive 
14
act or practice in violation of section 5(a)(1) of 
15
the Federal Trade Commission Act (15 U.S.C. 
16
45(a)(1)). 
17
(B) POWERS OF COMMISSION.—Except as 
18
provided in subparagraph (C) and paragraphs 
19
(1)(B) and (3)— 
20
(i) the Commission shall enforce this 
21
section in the same manner, by the same 
22
means, and with the same jurisdiction, 
23
powers, and duties as though all applicable 
24
terms and provisions of the Federal Trade 
25
01:30 Mar 19, 2019
H1499
5 
•HR 1499 IH
Commission Act (15 U.S.C. 41 et seq.) 
1
were incorporated into and made a part of 
2
this section; and 
3
(ii) any NDA or BLA holder or subse-
4
quent filer that violates this section shall 
5
be subject to the penalties and entitled to 
6
the privileges and immunities provided in 
7
the Federal Trade Commission Act. 
8
(C) JUDICIAL REVIEW.—In the case of a 
9
cease and desist order issued by the Commis-
10
sion under section 5 of the Federal Trade Com-
11
mission Act (15 U.S.C. 45) for violation of this 
12
section, a party to such order may obtain judi-
13
cial review of such order as provided in such 
14
section 5, except that— 
15
(i) such review may only be obtained 
16
in— 
17
(I) the United States Court of 
18
Appeals for the District of Columbia 
19
Circuit; 
20
(II) the United States Court of 
21
Appeals for the circuit in which the 
22
ultimate parent entity, as defined in 
23
section 801.1(a)(3) of title 16, Code 
24
of Federal Regulations, or any suc-
25
01:30 Mar 19, 2019
H1499
6 
•HR 1499 IH
cessor thereto, of the NDA or BLA 
1
holder is incorporated as of the date 
2
that the application described in sub-
3
paragraph (A) or (B) of subsection 
4
(f)(8) is submitted to the Commis-
5
sioner of Food and Drugs; or 
6
(III) the United States Court of 
7
Appeals for the circuit in which the 
8
ultimate parent entity, as so defined, 
9
of the subsequent filer is incorporated 
10
as of the date that the application de-
11
scribed in subparagraph (A) or (B) of 
12
subsection (f)(8) is submitted to the 
13
Commissioner of Food and Drugs; 
14
and 
15
(ii) the petition for review shall be 
16
filed in the court not later than 30 days 
17
after such order is served on the party 
18
seeking review. 
19
(3) ADDITIONAL ENFORCEMENT AUTHORITY.— 
20
(A) CIVIL
PENALTY.—The Commission 
21
may commence a civil action to recover a civil 
22
penalty in a district court of the United States 
23
against any NDA or BLA holder or subsequent 
24
filer that violates this section. 
25
01:30 Mar 19, 2019
H1499
7 
•HR 1499 IH
(B) SPECIAL
RULE
FOR
RECOVERY
OF 
1
PENALTY
IF
CEASE
AND
DESIST
ORDER 
2
ISSUED.— 
3
(i) IN GENERAL.—If the Commission 
4
has issued a cease and desist order in a 
5
proceeding under section 5 of the Federal 
6
Trade Commission Act (15 U.S.C. 45) for 
7
violation of this section— 
8
(I) the Commission may com-
9
mence a civil action under subpara-
10
graph (A) to recover a civil penalty 
11
against any party to such order at 
12
any time before the expiration of the 
13
1-year period beginning on the date 
14
on which such order becomes final 
15
under section 5(g) of such Act (15 
16
U.S.C. 45(g)); and 
17
(II) in such civil action, the find-
18
ings of the Commission as to the ma-
19
terial facts in such proceeding shall be 
20
conclusive, unless— 
21
(aa) the terms of such order 
22
expressly provide that the Com-
23
mission’s findings shall not be 
24
conclusive; or 
25
01:30 Mar 19, 2019
H1499
8 
•HR 1499 IH
(bb) such order became final 
1
by reason of section 5(g)(1) of 
2
such Act (15 U.S.C. 45(g)(1)), in 
3
which case such findings shall be 
4
conclusive if supported by evi-
5
dence. 
6
(ii) RELATIONSHIP TO PENALTY FOR 
7
VIOLATION
OF
AN
ORDER.—The penalty 
8
provided in clause (i) for violation of this 
9
section is separate from and in addition to 
10
any penalty that may be incurred for viola-
11
tion of an order of the Commission under 
12
section 5(l) of the Federal Trade Commis-
13
sion Act (15 U.S.C. 45(l)). 
14
(C) AMOUNT OF PENALTY.— 
15
(i) IN GENERAL.—The amount of a 
16
civil penalty imposed in a civil action under 
17
subparagraph (A) on a party to an agree-
18
ment described in subsection (a) shall be 
19
sufficient to deter violations of this section, 
20
but in no event greater than— 
21
(I) if such party is the NDA or 
22
BLA holder, the greater of— 
23
(aa) 3 times the value re-
24
ceived by such NDA or BLA 
25
01:30 Mar 19, 2019
H1499
9 
•HR 1499 IH
holder that is reasonably attrib-
1
utable to the violation of this sec-
2
tion; or 
3
(bb) 3 times the value given 
4
to the subsequent filer reasonably 
5
attributable to the violation of 
6
this section; and 
7
(II) if such party is the subse-
8
quent filer, 3 times the value received 
9
by such subsequent filer that is rea-
10
sonably attributable to the violation of 
11
this section. 
12
(ii) FACTORS FOR CONSIDERATION.— 
13
In determining such amount, the court 
14
shall take into account— 
15
(I) the nature, circumstances, ex-
16
tent, and gravity of the violation; 
17
(II) with respect to the violator, 
18
the degree of culpability, any history 
19
of violations, the ability to pay, any 
20
effect on the ability to continue doing 
21
business, profits earned by the NDA 
22
or BLA holder, compensation received 
23
by the subsequent filer, and the 
24
amount of commerce affected; and 
25
01:30 Mar 19, 2019
H1499
10 
•HR 1499 IH
(III) other matters that justice 
1
requires. 
2
(D) INJUNCTIONS AND OTHER EQUITABLE 
3
RELIEF.—In a civil action under subparagraph 
4
(A), the United States district courts are em-
5
powered to grant mandatory injunctions and 
6
such other and further equitable relief as they 
7
deem appropriate. 
8
(4) REMEDIES
IN
ADDITION.—Remedies pro-
9
vided in this subsection are in addition to, and not 
10
in lieu of, any other remedy provided by Federal 
11
law. 
12
(5) PRESERVATION OF AUTHORITY OF COMMIS-
13
SION.—Nothing in this section shall be construed to 
14
affect any authority of the Commission under any 
15
other provision of law. 
16
(e) ANTITRUST LAWS.—Nothing in this section shall 
17
modify, impair, limit, or supersede the applicability of the 
18
antitrust laws as defined in subsection (a) of the first sec-
19
tion of the Clayton Act (15 U.S.C. 12(a)), and of section 
20
5 of the Federal Trade Commission Act (15 U.S.C. 45) 
21
to the extent that such section 5 applies to unfair methods 
22
of competition. Nothing in this section shall modify, im-
23
pair, limit, or supersede the right of a subsequent filer 
24
to assert claims or counterclaims against any person, 
25
01:30 Mar 19, 2019
H1499
11 
•HR 1499 IH
under the antitrust laws or other laws relating to unfair 
1
competition. 
2
(f) DEFINITIONS.—In this section: 
3
(1) AGREEMENT
RESOLVING
OR
SETTLING
A 
4
COVERED
PATENT
INFRINGEMENT
CLAIM.—The 
5
term ‘‘agreement resolving or settling a covered pat-
6
ent infringement claim’’ means any agreement 
7
that— 
8
(A) resolves or settles a covered patent in-
9
fringement claim; or 
10
(B) is contingent upon, provides for a con-
11
tingent condition for, or is otherwise related to 
12
the resolution or settlement of a covered patent 
13
infringement claim. 
14
(2) COMMISSION.—The term ‘‘Commission’’ 
15
means the Federal Trade Commission. 
16
(3) COVERED PATENT INFRINGEMENT CLAIM.— 
17
The term ‘‘covered patent infringement claim’’ 
18
means an allegation made by the NDA or BLA hold-
19
er to a subsequent filer, whether or not included in 
20
a complaint filed with a court of law, that— 
21
(A) the submission of the application de-
22
scribed in clause (i) or (ii) of paragraph (5)(A), 
23
or the manufacture, use, offering for sale, sale, 
24
or importation into the United States of a cov-
25
01:30 Mar 19, 2019
H1499
12 
•HR 1499 IH
ered product that is the subject of such an ap-
1
plication, infringes any patent owned by, or ex-
2
clusively licensed to, the NDA or BLA holder of 
3
the covered product; or 
4
(B) the covered product to be manufac-
5
tured under such application uses a covered 
6
product as claimed in a published patent appli-
7
cation. 
8
(4) COVERED
PRODUCT.—The term ‘‘covered 
9
product’’ means— 
10
(A) a new drug (as defined in section 
11
201(p) of the Federal Food, Drug, and Cos-
12
metic Act (21 U.S.C. 321(p))); or 
13
(B) a biological product (as defined in sec-
14
tion 351(i) of the Public Health Service Act (42 
15
U.S.C. 262(i))). 
16
(5) NDA OR BLA HOLDER.—The term ‘‘NDA 
17
or BLA holder’’ means— 
18
(A) the holder of— 
19
(i) an approved new drug application 
20
filed under section 505(b)(1) of the Fed-
21
eral Food, Drug, and Cosmetic Act (21 
22
U.S.C. 355(b)(1)) for a covered product; 
23
or 
24
01:30 Mar 19, 2019
H1499
13 
•HR 1499 IH
(ii) an application approved under sec-
1
tion 351(a) of the Public Health Service 
2
Act (42 U.S.C. 262(a)) with respect to a 
3
biological product; 
4
(B) a person owning or controlling enforce-
5
ment of the patent on— 
6
(i) the list published under section 
7
505(j)(7) of the Federal Food, Drug, and 
8
Cosmetic Act (21 U.S.C. 355(j)(7)) in con-
9
nection with the application described in 
10
subparagraph (A)(i); or 
11
(ii) the equivalent list published under 
12
section 351 of the Public Health Service 
13
Act (42 U.S.C. 262) comprised of patents 
14
associated with applications filed under 
15
section 351(a) of such Act (42 U.S.C. 
16
262(a)); or 
17
(C) the predecessors, subsidiaries, divi-
18
sions, groups, and affiliates controlled by, con-
19
trolling, or under common control with any en-
20
tity described in subparagraph (A) or (B) (such 
21
control to be presumed by direct or indirect 
22
share ownership of 50 percent or greater), as 
23
well as the licensees, licensors, successors, and 
24
assigns of each of the entities. 
25
01:30 Mar 19, 2019
H1499
14 
•HR 1499 IH
(6) PATENT.—The term ‘‘patent’’ means a pat-
1
ent issued by the United States Patent and Trade-
2
mark Office. 
3
(7) 
STATUTORY
EXCLUSIVITY.—The 
term 
4
‘‘statutory exclusivity’’ means those prohibitions on 
5
the approval of drug applications under clauses (ii) 
6
through (iv) of section 505(c)(3)(E) (5- and 3-year 
7
data exclusivity), section 505(j)(5)(B)(iv) (180-day 
8
exclusivity), section 527 (orphan drug exclusivity), 
9
section 505A (pediatric exclusivity), or section 505E 
10
(qualified infectious disease product exclusivity) of 
11
the Federal Food, Drug, and Cosmetic Act (21 
12
U.S.C. 355(c)(3)(E), 355(j)(5)(B)(iv), 360cc, 355a, 
13
355f), or section 351(k)(6) (interchangeable biologi-
14
cal product exclusivity) or section 351(k)(7) (biologi-
15
cal product reference product exclusivity) of the 
16
Public Health Service Act (42 U.S.C. 262(k)(6), 
17
(7)). 
18
(8) SUBSEQUENT
FILER.—The term ‘‘subse-
19
quent filer’’ means— 
20
(A) in the case of a drug, a party that 
21
owns or controls an abbreviated new drug appli-
22
cation filed under section 505(j) of the Federal 
23
Food, Drug, and Cosmetic Act (21 U.S.C. 
24
355(j)) or a new drug application filed under 
25
01:30 Mar 19, 2019
H1499
15 
•HR 1499 IH
section 505(b)(2) of such Act (21 U.S.C. 
1
355(b)(2)) or has the exclusive rights to dis-
2
tribute the covered product that is the subject 
3
of such application; or 
4
(B) in the case of a biological product, a 
5
party that owns or controls an application filed 
6
with the Food and Drug Administration under 
7
section 351(k) of the Public Health Service Act 
8
(42 U.S.C. 262(k)) or has the exclusive rights 
9
to distribute the biological product that is the 
10
subject of such application. 
11
(g) EFFECTIVE DATE.—This section shall apply to 
12
all agreements described in subsection (a) entered into 
13
after June 17, 2013, except that a civil penalty may only 
14
be obtained under subsection (d)(3)(A) with respect to 
15
such an agreement entered into on or after the date of 
16
enactment of this Act. 
17
SEC. 3. NOTICE AND CERTIFICATION OF AGREEMENTS. 
18
(a) NOTICE OF ALL AGREEMENTS.—Section 1111(7) 
19
of the Medicare Prescription Drug, Improvement, and 
20
Modernization Act of 2003 (21 U.S.C. 355 note) is 
21
amended by inserting ‘‘or the owner of a patent for which 
22
a claim of infringement could reasonably be asserted 
23
against any person for making, using, offering to sell, sell-
24
ing, or importing into the United States a biological prod-
25
01:30 Mar 19, 2019
H1499
16 
•HR 1499 IH
uct that is the subject of a biosimilar biological product 
1
application’’ before the period at the end. 
2
(b) CERTIFICATION OF AGREEMENTS.—Section 1112 
3
of such Act (21 U.S.C. 355 note) is amended by adding 
4
at the end the following: 
5
‘‘(d) CERTIFICATION.—The Chief Executive Officer 
6
or the company official responsible for negotiating any 
7
agreement under subsection (a) or (b) that is required to 
8
be filed under subsection (c) shall, within 30 days of such 
9
filing, execute and file with the Assistant Attorney General 
10
and the Commission a certification as follows: ‘I declare 
11
that the following is true, correct, and complete to the best 
12
of my knowledge: The materials filed with the Federal 
13
Trade Commission and the Department of Justice under 
14
section 1112 of the Medicare Prescription Drug, Improve-
15
ment, and Modernization Act of 2003, with respect to the 
16
agreement referenced in this certification— 
17
‘‘ ‘(1) represent the complete, final, and exclu-
18
sive agreement between the parties; 
19
‘‘ ‘(2) include any ancillary agreements that are 
20
contingent upon, provide a contingent condition for, 
21
were entered into within 30 days of, or are otherwise 
22
related to, the referenced agreement; and 
23
‘‘ ‘(3) include written descriptions of any oral 
24
agreements, representations, commitments, or prom-
25
01:30 Mar 19, 2019
H1499
17 
•HR 1499 IH
ises between the parties that are responsive to sub-
1
section (a) or (b) of such section 1112 and have not 
2
been reduced to writing.’.’’. 
3
SEC. 4. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD. 
4
Section 505(j)(5)(D)(i)(V) of the Federal Food, 
5
Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)(V)) 
6
is amended by inserting ‘‘section 2 of the Protecting Con-
7
sumer Access to Generic Drugs Act of 2019 or’’ after 
8
‘‘that the agreement has violated’’. 
9
SEC. 5. COMMISSION LITIGATION AUTHORITY. 
10
Section 16(a)(2) of the Federal Trade Commission 
11
Act (15 U.S.C. 56(a)(2)) is amended— 
12
(1) in subparagraph (D), by striking ‘‘or’’ after 
13
the semicolon; 
14
(2) in subparagraph (E), by inserting ‘‘or’’ 
15
after the semicolon; and 
16
(3) by inserting after subparagraph (E) the fol-
17
lowing: 
18
‘‘(F) under section 2(d)(3)(A) of the Pro-
19
tecting Consumer Access to Generic Drugs Act 
20
of 2019;’’. 
21
SEC. 6. STATUTE OF LIMITATIONS. 
22
(a) IN GENERAL.—Except as provided in subsection 
23
(b), the Commission shall commence any administrative 
24
proceeding or civil action to enforce section 2 of this Act 
25
01:30 Mar 19, 2019
H1499
18 
•HR 1499 IH
not later than 6 years after the date on which the parties 
1
to the agreement file the Notice of Agreement as provided 
2
by section 1112(c)(2) and (d) of the Medicare Prescription 
3
Drug Improvement and Modernization Act of 2003 (21 
4
U.S.C. 355 note). 
5
(b) CIVIL ACTION AFTER ISSUANCE OF CEASE AND 
6
DESIST ORDER.—If the Commission has issued a cease 
7
and desist order under section 5 of the Federal Trade 
8
Commission Act (15 U.S.C. 45) for violation of section 
9
2 of this Act and the proceeding for the issuance of such 
10
order was commenced within the period required by sub-
11
section (a) of this section, such subsection does not pro-
12
hibit the commencement, after such period, of a civil ac-
13
tion under section 2(d)(3)(A) against a party to such 
14
order or a civil action under subsection (l) of such section 
15
5 for violation of such order. 
16
Æ 
01:30 Mar 19, 2019
H1499
